Medical device companies have emerged as unexpected beneficiaries of the market rotation away from AI-heavy technology stocks. Companies like Medtronic, Boston Scientific, and Edwards Lifesciences have outperformed the broader market by 8-12% over the past quarter. [1]

The rotation reflects a fundamental reassessment of what investors value. Medical device makers offer predictable revenue streams, established customer relationships, and regulatory barriers that protect margins. These qualities have become more attractive as AI company valuations face scrutiny. [1]

The healthcare sector's appeal lies in its recession-resistant characteristics. Hospitals continue purchasing essential equipment regardless of economic cycles. Aging populations in developed markets ensure sustained demand. The regulatory approval process creates moats that technology competitors cannot easily cross. [2]

The rotation is not merely defensive. Medical device companies are increasingly adopting AI in their own products — surgical robots, diagnostic imaging, and patient monitoring systems. The sector benefits from AI's capabilities without bearing the infrastructure costs that are straining hyperscaler balance sheets. [2]

For investors, the medical device rotation represents a bet that boring consistency will outperform exciting uncertainty. The market is pricing in the possibility that AI's promise is overstated — and positioning accordingly. [1]

-- THEO KAPLAN, San Francisco